Albuminex (Bio Products Laboratory) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) The albuminex market is poised for growth due to rising liver disease prevalence, increasing chronic disease burden, expanding specialty hospitals, and improved plasma collection networks. Additionally, rising liver cancer incidence, healthcare expenditure, and pharmaceutical research are key drivers, while tariffs and local plasma investments further shape the market dynamics.

Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Albuminex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The Albuminex Market Global Report 2026 serves as a pivotal resource for strategists, marketers, and senior management, equipping them with crucial insights into a burgeoning market. This comprehensive report provides a strategic guide to understanding the trends poised to influence the market over the next decade and beyond.

The global albuminex market is experiencing significant growth, driven by various factors across both the historic and forecast periods. Historically, this growth has been fueled by the established therapeutic role of albumin, increasing prevalence of liver diseases, and advancements in hospital admissions and clinical protocols. Modern plasma fractionation technologies have also played a crucial role. Looking forward, the market is expected to benefit from the increasing chronic disease burden, expansion of specialty hospitals, and enhanced plasma collection networks. The rise in healthcare expenditures further supports this market's expansion.

One of the critical factors propelling albuminex market growth is the rising incidence of liver cancer. This condition is often linked to risk factors such as chronic hepatitis infections, obesity, alcohol consumption, and an aging population. Albuminex is instrumental in managing fluid imbalances and maintaining oncotic pressure in liver cancer patients, mitigating complications like ascites and edema. As per Cancer Research UK, new liver cancer cases are projected to escalate from 7,600 annually in 2023-2025 to 9,700 by 2038-2040, indicating a rising market demand for albuminex.

Increasing healthcare expenditure worldwide is another pivotal factor. According to the UK's Office for National Statistics, healthcare spending grew by 5.6% in 2023 compared to the previous year. This trend supports greater availability and use of albuminex in medical facilities and enhances treatment capacities by adopting advanced therapeutic solutions.

The albuminex market is also benefitting from an upsurge in pharmaceutical and medicinal research activities. These endeavors, spurred by technological advancements and healthcare demands, are facilitating the development of novel albumin-based therapies. They are also enhancing manufacturing processes and expanding clinical applications including drug delivery systems and critical care. Data from the European Federation of Pharmaceutical Industries and Associations highlight North America's commanding share of 53.3% in global pharmaceutical sales as of 2023.

Key market participants include Bio Products Laboratory Limited, with North America leading the market in 2025. Meanwhile, Asia-Pacific is the fastest-growing region during the forecast period. The regions analyzed in the albuminex market report include Asia-Pacific, Western and Eastern Europe, North and South America, the Middle East, and Africa.

Report Scope:

• Type: Human Serum Albumin, Bovine Serum Albumin, Recombinant Human Serum Albumin
• Clinical Indication: Hypovolemia, Hypoalbuminemia, and more.
• Distribution Channel: Hospital Pharmacies, Retail and Specialty Pharmacies, Online Pharmacies
• End User: Hospitals and Clinics, Pharma and Biotech Industry, Research Institutes

Major Trends

• Broad Clinical Use of Human Albumin Products
• Rising Demand in Hypovolemia Management
• Increased Application in Liver and Renal Disorders
• Expansion of Plasma Based Therapeutics
• Growth of Hospital Based Infusion Therapies

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11052026004107003653ID1111097441